Our formulary list is updating on July 1, 2025 to include biosimilar medications as a substitute for Stelara. These biosimilars provide the same clinical effectiveness at a reduced cost, allowing you to save money while managing conditions such as:
- Plaque psoriasis
- Psoriatic arthritis
- Crohn's disease
- Ulcerative colitis
To find out how much you can save, visit your online account.
The preferred biosimilars for brand name Stelara are:
- Selarsdi (ustekinumab-aekn)
- Steqeyma (ustekinumab-stba)
- Yesintek (ustekinumab-kfce)
What this means for members
- If you have a prescription for Stelara, you will receive a letter before the change takes effect.
- You won’t need a new prior authorization (PA) for a biosimilar. New PAs for biosimilars will be proactively entered by Prime Therapeutics on July 1, 2025. The new PA will be valid until the date of the original Stelara PA.
- If you believe Stelara is medically necessary, you or your provider can submit a new PA for review after July 1, 2025.
Keeping pharmacies up to date
Pharmacies will be informed about the change in formulary coverage of Stelara. This notification will detail the safety and effectiveness of these biosimilars.
If you have any questions, please call Member Services: 844-363-8457.
